





## LISTING OF CLAIMS

### CLAIMS 1-19 (CANCELED)

20- (previously presented) A compound of formula (I) :



wherein :



wherein R<sub>1</sub> and R'<sub>1</sub>, which may be identical or different, each represents linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, linear or branched (C<sub>2</sub>-C<sub>6</sub>)alkenyl, linear or branched (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl-(C<sub>1</sub>-C<sub>6</sub>)alkyl in which the alkyl moiety may be linear or branched, aryl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl in which the alkyl moiety may be linear or branched, heteroaryl or heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl in which the alkyl moiety may be linear or branched,

and R<sub>2</sub> represents hydrogen or linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl,

it being possible, for R<sub>1</sub> and R<sub>2</sub> together to form a linear or branched alkylene chain having from 3 to 6 carbon atoms,

- ◆ R<sub>3</sub> represents linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxy,
- ◆ R<sub>4</sub> represents halogen, hydroxy, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxy or amino optionally substituted by one or two linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl,
- ◆ p is 1, 2 or 3,


it being understood that :

- "aryl" denotes phenyl, naphthyl or biphenyl,
- "heteroaryl" denotes a mono- or bi-cyclic aromatic group having from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen,

wherein the aryl and heteroaryl groups so defined may be substituted by from 1 to 3 groups selected from linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, carboxy, formyl, nitro, cyano, linear or branched polyhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, alkoxycarbonyl and halogen,

its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

21- (currently amended) A compound of Claim ~~19~~ 20, wherein A represents



22- (currently amended) A compound of Claim ~~19~~ 20, wherein R<sub>1</sub> represents linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl.

23- (currently amended) A compound of Claim ~~19~~ 20, wherein R<sub>1</sub> represents (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl.

24- (currently amended) A compound of Claim ~~19~~ 20, wherein R<sub>2</sub> represents hydrogen.

25- (currently amended) A compound of Claim ~~19~~ 20, wherein p is 2.

26- (currently amended) A compound of Claim ~~19~~ 20, wherein R<sub>3</sub> represents methoxy.

27- (currently amended) A compound of Claim ~~19~~ 20, wherein R<sub>4</sub> represents OH.

28- (currently amended) A compound of Claim 49 20, wherein R<sub>4</sub> represents OMe.

29- (currently amended) A compound of Claim 49 20, wherein R<sub>4</sub> represents NH<sub>2</sub>.


30- (currently amended) A compound of Claim 49 20, wherein R<sub>4</sub> represents halogen.

31- (currently amended) A compound of Claim 49 20, wherein the -CH<sub>2</sub>R<sub>4</sub> group is in the  
5 3 position (meta) of the phenyl group.


32- (currently amended) A compound of Claim 49 20, which is selected from *N*-(2-{3-[3-(hydroxymethyl)phenyl]-7-methoxy-1-naphthyl}ethyl)acetamide, and addition salts thereof with a pharmaceutically-acceptable acid or base.

33- (currently amended) A compound of Claim 49 20, which is selected from *N*-(2-{3-[3-(aminomethyl)phenyl]-7-methoxy-1-naphthyl}ethyl)acetamide, and addition salts thereof with a pharmaceutically-acceptable acid or base.  
10

34- (previously presented) A compound of formula (V') :



wherein



wherein R<sub>1</sub> and R'<sub>1</sub>, which may be identical or different, each represents linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, linear or branched (C<sub>2</sub>-C<sub>6</sub>)alkenyl, linear or branched

(C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl-(C<sub>1</sub>-C<sub>6</sub>)alkyl in which the alkyl moiety may be linear or branched, aryl, aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl in which the alkyl moiety may be linear or branched, heteroaryl or heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl in which the alkyl moiety may be linear or branched,

and R<sub>2</sub> represents hydrogen or linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl,

it being possible, for R<sub>1</sub> and R<sub>2</sub> together to form a linear or branched alkylene chain having from 3 to 6 carbon atoms,

♦ R<sub>3</sub> represents linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxy,

♦ R'<sub>5</sub> represents linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl or formyl,

its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

**35-** (currently amended) A method of treating a living animal body, including a human, afflicted with a disorder of the melatoninerpic system comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 19 20 which is effective for alleviation of the disorder.

**36-** (currently amended) A method of treating a living animal body, including a human, afflicted with a condition selected from sleep disorders, stress, anxiety, seasonal affective disorders or severe depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory losses, Alzheimer's disease, cerebral circulation disorders, and also sexual dysfunctions, ovulation and immunomodulation disorders and cancers, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 19 20 which is effective for alleviation of the condition.

**37-** (currently amended) A pharmaceutical composition useful for treating melatoninerpic disorders comprising as active principle an effective amount of a compound of Claim 19 20, together with one or more pharmaceutically-acceptable excipients or vehicles.

**38**- (currently amended) A method of treating a living animal body, including a human, afflicted with a disorder of the melatoninergetic system comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim ~~33~~ 34 which is effective for alleviation of the disorder.

**39**- (currently amended) A method of treating a living animal body, including a human, afflicted with a condition selected from sleep disorders, stress, anxiety, seasonal affective disorders or severe depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory losses, Alzheimer's disease, cerebral circulation disorders, and also sexual dysfunctions, ovulation and immunomodulation disorders and cancers, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim ~~33~~ 34 which is effective for alleviation of the condition.

5     **40**- (currently amended) A pharmaceutical composition useful for treating melatoninergetic disorders comprising as active principle an effective amount of a compound of Claim ~~33~~ 34, together with one or more pharmaceutically-acceptable excipients or vehicles.